Rizatriptan

How to order Rizatriptan

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Rizatriptan on Prescriptsy

Rizatriptan is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine attacks with or without aura in adults.

It belongs to the triptan class of medicines, which are considered the gold-standard treatment for moderate to severe migraine when simple analgesics have not provided adequate relief.

Rizatriptan is available as standard tablets (5 mg and 10 mg) and orodispersible wafers (10 mg) that dissolve on the tongue without water, making it particularly convenient for patients who experience nausea during attacks.

It is a prescription-only medicine (POM) in the United Kingdom, available as a generic or under the brand name Maxalt (Organon).

Migraine is a complex neurological condition that affects approximately 1 in 7 people worldwide.

In the United Kingdom, an estimated 10 million people experience migraine, making it the third most common disease globally according to the Global Burden of Disease Study.

Migraine attacks cause throbbing, often one-sided headache, typically accompanied by nausea, vomiting, and heightened sensitivity to light (photophobia) and sound (phonophobia).

Attacks last between 4 and 72 hours if untreated and can be profoundly disabling, affecting work, education, relationships, and quality of life.

This page provides a comprehensive clinical guide to rizatriptan, covering how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about rizatriptan

Before reading further, please note these essential safety points.

• Rizatriptan must not be used by patients with a history of heart attack, stroke, angina, transient ischaemic attack, peripheral vascular disease, or uncontrolled high blood pressure.
• Do not take rizatriptan within 24 hours of another triptan or ergotamine-containing medicine.
• If you take propranolol, the rizatriptan dose must be reduced to 5 mg.
• Overuse of acute migraine treatments (10 or more days per month for 3 months or longer) can cause medication-overuse headache.
• Chest tightness after taking a triptan is usually benign but should be evaluated if severe or persistent.

Understanding migraine

Migraine is a primary headache disorder with a strong genetic component.

It is caused by abnormal activation of the trigeminovascular system, a network of sensory nerves that innervate the blood vessels of the meninges (the membranes covering the brain).

During a migraine attack, trigeminal nerve fibres release vasoactive neuropeptides, most notably calcitonin gene-related peptide (CGRP), which cause vasodilation, neurogenic inflammation, and sensitisation of pain pathways.

The result is the characteristic throbbing headache and associated symptoms.

About one-third of migraine sufferers experience aura, which consists of fully reversible neurological symptoms (most commonly visual disturbances such as zigzag lines, flashing lights, or scotomata) that typically precede the headache by 5 to 60 minutes.

The NICE guideline on headaches (CG150) recommends a stepwise approach to acute migraine treatment.

For mild to moderate attacks, simple analgesics (aspirin 900 mg, ibuprofen 400 mg, or paracetamol 1000 mg) are first-line, preferably combined with an anti-emetic if nausea is present.

For moderate to severe attacks, or when simple analgesics have failed, a triptan should be offered.

NICE recommends offering a triptan early in the treatment pathway rather than reserving it as a last resort.

How rizatriptan works

Rizatriptan is a selective agonist at serotonin 5-HT1B and 5-HT1D receptors.

These receptor subtypes are found on meningeal blood vessels, trigeminal nerve terminals, and within the trigeminal nucleus caudalis in the brainstem.

Activation of 5-HT1B receptors on dilated meningeal arteries causes vasoconstriction, reversing the pathological vasodilation that contributes to migraine headache.

Activation of 5-HT1D receptors on trigeminal nerve endings inhibits the release of pro-inflammatory neuropeptides (including CGRP and substance P), thereby reducing neurogenic inflammation.

Rizatriptan also inhibits the transmission of pain signals through second-order neurones in the trigeminal nucleus caudalis, reducing the central processing of migraine pain.

After oral administration, rizatriptan is rapidly absorbed. Standard tablets reach peak plasma concentration in approximately 1 to 1.5 hours, while orodispersible wafers peak at 1.6 to 2.5 hours.

The oral bioavailability is approximately 40% to 45%. Rizatriptan is primarily metabolised by monoamine oxidase A (MAO-A), with an elimination half-life of approximately 2 to 3 hours.

This relatively short half-life means that clinical effects last approximately 4 to 6 hours, which is usually sufficient for most migraine attacks but may contribute to headache recurrence in some patients.

Clinical evidence for rizatriptan

Rizatriptan has been extensively studied in large randomised controlled trials.

In pivotal trials, rizatriptan 10 mg provided headache relief (reduction from moderate or severe to mild or no pain) at 2 hours in approximately 67% to 77% of patients, compared with approximately 23% to 40% for placebo.

Complete pain freedom at 2 hours was achieved in approximately 35% to 45% of patients.

A landmark network meta-analysis published in The Lancet comparing all available triptans found that rizatriptan 10 mg was among the most effective triptans for pain freedom at 2 hours and sustained pain freedom at 24 hours, alongside eletriptan 80 mg and almotriptan 12.5 mg.

The consistency of response across multiple attacks is an important consideration.

Studies show that rizatriptan provides consistent relief across sequential migraine attacks, with response rates remaining stable over time.

If rizatriptan fails on one occasion, it may still be effective for subsequent attacks.

However, if it consistently fails to provide adequate relief after 3 treated attacks, NICE recommends trying a different triptan, as individual response to different triptans varies.

Rizatriptan compared with other triptans

Seven triptans are available in the United Kingdom: sumatriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, frovatriptan, and naratriptan.

They share the same mechanism of action but differ in pharmacokinetic properties, speed of onset, duration of effect, and available formulations.

Rizatriptan is among the fastest-acting oral triptans, with onset of relief within 30 minutes for many patients.

Sumatriptan is the most widely known triptan and is available over the counter as 50 mg tablets (Imigran Recovery) in the UK, while rizatriptan requires a prescription.

Eletriptan may be marginally more effective than rizatriptan in some analyses but has more drug interactions.

Naratriptan and frovatriptan have slower onset but longer duration, making them suitable for patients with prolonged migraine attacks or menstrual migraine.

The orodispersible wafer formulation of rizatriptan is a practical advantage for patients who experience nausea or vomiting early in their attacks, as it dissolves on the tongue and does not require swallowing a tablet with water.

Zolmitriptan also has an orodispersible formulation and a nasal spray, while sumatriptan is available as a nasal spray and subcutaneous injection for patients who cannot take oral medication.

Dosage and administration

The standard dose is rizatriptan 10 mg, taken as early as possible after the headache phase begins. For standard tablets, swallow with water.

For the orodispersible wafer, place on the tongue and allow it to dissolve, then swallow with saliva. Water is not needed.

If the headache improves but returns, a second 10 mg dose may be taken after at least 2 hours, up to a maximum of 20 mg in 24 hours.

If the first dose provides no relief at all, do not take a second dose for that attack.

Rizatriptan should not be taken during the aura phase before the headache develops.

If you take propranolol for migraine prevention, the dose of rizatriptan must be reduced to 5 mg per dose (maximum 10 mg in 24 hours), because propranolol significantly increases rizatriptan plasma concentrations.

Other beta-blockers do not require a dose adjustment. Rizatriptan is not recommended for children or adolescents under 18.

Side effects of rizatriptan

Common side effects

Dizziness, drowsiness, fatigue, and weakness are the most commonly reported side effects. These are usually mild and resolve within a few hours.

Nausea may occur but is often difficult to distinguish from migraine-related nausea. Dry mouth, abdominal discomfort, and flushing have been reported.

Triptan sensations

Approximately 5% to 10% of triptan users experience sensations of tingling, numbness, warmth, heaviness, pressure, or tightness, which may affect the chest, throat, jaw, neck, or limbs.

These are generally benign and do not indicate cardiac ischaemia, but persistent or severe chest symptoms should be evaluated.

In extremely rare cases, triptans have caused coronary artery vasospasm or myocardial infarction, almost exclusively in patients with unrecognised cardiovascular disease.

Medication-overuse headache

Using rizatriptan or any acute headache treatment on 10 or more days per month for 3 consecutive months or longer can lead to medication-overuse headache (MOH).

This condition paradoxically increases headache frequency and severity. If your migraine frequency is high enough to risk MOH, discuss preventive migraine treatment with your prescriber.

NICE recommends considering preventive treatment for patients experiencing 4 or more migraine days per month.

When to seek medical advice

Seek emergency help by calling 999 if you experience severe chest pain, sudden severe headache unlike anything you have had before, weakness or numbness on one side of your body, or difficulty speaking.

Contact your GP or call NHS 111 for persistent or worsening symptoms. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Cardiovascular contraindications

Rizatriptan must not be used by anyone with ischaemic heart disease, Prinzmetal angina (coronary vasospasm), previous myocardial infarction, cerebrovascular disease (stroke, TIA), peripheral vascular disease, or uncontrolled hypertension.

Patients with multiple cardiovascular risk factors should have a cardiovascular assessment before the first dose.

The vasoconstrictor properties of triptans mean that they could theoretically worsen ischaemia in vulnerable patients, although serious cardiovascular events with triptans are extremely rare in appropriately selected patients.

Drug interactions

Do not use rizatriptan within 24 hours of another triptan or ergotamine preparation. Do not use within 2 weeks of an MAOI.

The propranolol interaction requires a dose reduction to 5 mg. SSRIs and SNRIs may rarely cause serotonin syndrome when combined with triptans.

The MHRA advises awareness of the risk but does not contraindicate the combination if clinically appropriate. Discuss all your medicines with your prescriber before starting rizatriptan.

Special populations

Pregnancy: rizatriptan is not routinely recommended in pregnancy due to limited data. Paracetamol is the preferred first-line analgesic for migraine during pregnancy.

Breastfeeding: avoid breastfeeding for 24 hours after a dose. Liver impairment: mild to moderate hepatic impairment does not require dose adjustment; rizatriptan is contraindicated in severe hepatic impairment.

Renal impairment: no dose adjustment needed for mild to moderate renal impairment. Elderly: limited data in patients over 65; use with caution.

How to get rizatriptan in the UK

Rizatriptan is available on NHS prescription from your GP, neurologist, headache clinic, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Unlike sumatriptan 50 mg, rizatriptan is not available over the counter and requires a prescription. Generic rizatriptan is widely available and significantly less expensive than branded Maxalt.

Sources

• Rizatriptan 10 mg tablets, Summary of Product Characteristics (EMC)
• Rizatriptan, British National Formulary (BNF)
• Headaches in over 12s: diagnosis and management, NICE CG150
• Migraine, NHS
• MHRA Yellow Card Scheme